

**Program Agenda**  
**27<sup>th</sup> Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting**  
**May 28-31, 2025**

NOTE: Entire program constitutes 18.00 hours (1.8 CEU) for pharmacists, 18.00 AMA PRA Category 1 Credits™  
 "AASP" denotes an Advanced Antimicrobial Stewardship Program session

<b>Wednesday, May 28, 2025</b>	
<b>12:00 pm – 8:00 pm</b>	<b>Registration Desk</b>
<b>1:00 pm – 3:30 pm</b>	<p><b>Trainee Premeeting Session:</b> <i>(not CE accredited)</i></p> <p><b>Career Development and Networking Workshop</b>  <b>Invited Research Platform</b></p> <p>Moderator: Susan L. Davis, PharmD            Panelists: To be announced</p>
<b>3:30 pm – 4:00 pm</b>	<b>Break</b>
<b>4:00 pm – 6:00 pm</b>	<p><b>Classrooms #1- 4</b>  <i>All Classrooms are 1 hour each then repeated, you may attend two of the four offered</i></p>
<b>Classroom 1A</b> <b>AASP</b>	<p><b>Applying Antimicrobial Stewardship in Fungal Infections</b>            ACPE Program #: 0485-0000-25-013-L01-P (1.0 Contact Hour)            ACPE Activity Type: Application</p> <p>Moderator: Michael J. Rybak, PharmD, MPH, PhD            Facilitator: Jerod L. Nagel, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Discuss common antifungal stewardship priorities in hospitalized patients</li> <li>2. List relevant metrics and outcomes for antifungal stewardship initiatives</li> <li>3. Apply evidence-based approaches to implementation of antimicrobial stewardship strategies in clinical scenarios with fungal infections</li> </ol>
<b>Classroom 1B</b>	<p><b>Using AI in Stewardship Education</b>            ACPE Program #: 0485-0000-25-014-L04-P (1.0 Contact Hour)            ACPE Activity Type: Application</p> <p>Moderator: Meghan N. Jeffres, PharmD            Facilitator: Timothy Aungst, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Describe the underlying principles of AI use in health professional education</li> <li>2. Identify basic competencies that antimicrobial stewardship professionals need related to AI</li> <li>3. Develop a plan for AI use in a learning experience considering both preceptor and learner perspectives</li> </ol>
<b>Classroom 1C</b> <b>AASP</b>	<p><b>NHSN AUR Applications, Time to Focus on AR</b>            ACPE Program #: 0485-0000-25-015-L01-P (1.0 Contact Hour)            ACPE Activity Type: Application</p> <p>Moderator: David R. Ha, PharmD            Facilitator: Elizabeth S. Dodds Ashley, PharmD, MHS</p>

	<p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. List the data requirements and analysis reports available in the NHSN AR Option</li> <li>2. Describe how to interpret and apply NHSN AR Antibiogram reports</li> <li>3. Use a clinical scenario to identify an opportunity to improve antibiotic use and resistance monitoring using the NHSN AR Option</li> </ol>
<p><b>Classroom 1D</b>  <b>AASP</b></p>	<p><b>Antimicrobial Formulary Decision Making, Considerations for New Therapies</b>  ACPE Program #: 0485-0000-25-016-L01-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Moderator: Susan L. Davis, PharmD  Facilitator: Rachel M. Kenney, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Explain clinical rationale for formulary restriction and preauthorization strategies for new antimicrobial therapies</li> <li>2. Identify best practices for balancing patient outcomes and access with formulary costs in the health system setting</li> <li>3. Apply evidence-based approaches to implementation of antimicrobial stewardship strategies in clinical scenarios with new therapeutic agents</li> </ol>
<p><b>6:30 pm – 8:00 pm</b></p>	<p><b>Welcome Reception</b></p>

<p><b>Thursday, May 29, 2025</b></p>	
<p><b>6:30 am – 6:30 pm</b></p>	<p><b>Registration/Hospitality Desk</b></p>
<p><b>7:00 am – 8:00 am</b></p>	<p><b>Continental Breakfast in Exhibit Hall</b></p>
<p><b>8:00 am – 10:00 am</b></p>	<p><b>Classrooms #5-8</b>  <i>All Classrooms are 1 hour each and then repeated; you may attend two of the four offered</i></p>
<p><b>Classroom 2A</b>  <b>AASP</b></p>	<p><b>Improving Outcomes in <i>C. difficile</i></b>  ACPE Program #: 0485-0000-25-017-L01-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Moderator: Kerry L. LaPlante, PharmD  Facilitator: Rachel M. Kenney, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Outline strategies to identify patients at high risk for development or recurrence of <i>Clostridioides difficile</i> infection</li> <li>2. Describe effective interventions to optimize use of newer and novel therapies for <i>C. difficile</i> treatment and prevention</li> <li>3. Apply evidence-based approaches to implementation of antimicrobial stewardship strategies in clinical scenarios with <i>C. difficile</i></li> </ol>
<p><b>Classroom 2B</b>  <b>AASP</b></p>	<p><b>Did We Just Become Best Friends? Microbiology Lab Collaborations with Antimicrobial Stewardship Teams</b>  ACPE Program #: 0485-0000-25-018-L01-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Moderator: Michael J. Rybak, PharmD, MPH, PhD  Facilitator: Erin K. McCreary, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Analyze patient cases or example clinical scenarios to identify specific areas where antimicrobial stewardship teams and microbiology laboratories can partner to improve patient outcomes</li> </ol>

	<ol style="list-style-type: none"> <li>2. Outline strategies for effective communication between antimicrobial stewardship teams and microbiology laboratories</li> <li>3. Discuss potential barriers to antimicrobial stewardship team and microbiology laboratory collaboration and strategies to overcome them</li> </ol>
<b>Classroom 2C</b> <b>AASP</b>	<p><b>Welcome to the Stewardship Team, Let's Prioritize Your Day</b>  ACPE Program #: 0485-0000-25-019-L04-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Moderator: Susan L. Davis, PharmD  Facilitator: Jamie L. Wagner, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Analyze the dynamics of interprofessional antimicrobial stewardship teams to identify barriers and opportunities for improving patient care strategies</li> <li>2. Evaluate the effectiveness of various technological tools in prioritizing and implementing antimicrobial stewardship interventions</li> <li>3. Create a workflow that integrates leadership strategies and administrative requirements into antimicrobial stewardship practices to enhance program efficiency</li> </ol>
<b>Classroom 2D</b> <b>AASP</b>	<p><b>Creating Stewardship Interventions with Antimicrobial Resistance Outcomes</b>  ACPE Program #: 0485-0000-25-020-L01-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Moderator: Meghan N. Jeffres, PharmD  Facilitator: Elizabeth S. Dodds Ashley, PharmD, MHS</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Summarize antimicrobial stewardship metrics and outcomes related to resistance</li> <li>2. List antimicrobial stewardship interventions with evidence of impact on resistance</li> <li>3. Given a clinical scenario, apply evidence-based approaches to improving antimicrobial resistance through antimicrobial stewardship practices</li> </ol>
<b>10:00 am – 10:30 am</b>	<b>Break in Exhibit Hall</b>
<b>10:00 am – 10:30 am</b>	<b>Exhibit Theater in Exhibit Hall</b>  <b>Title: Review of EMBLAVEO</b> Speaker: Jamie L. Wagner, PharmD Hosted by AbbVie Commercial
<b>10:30 am – 10:45 am</b>	<b>Welcome and Opening Remarks</b> Moderator: Michael J. Rybak, PharmD, MPH, PhD
<b>10:45 am – 11:45 am</b>	<p><b>Keynote: Digital Health and Infectious Diseases</b>  ACPE Program #: 0485-0000-25-021-L01-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Moderator: Kerry L. LaPlante, PharmD  Speaker: Timothy Aungst, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Describe emerging technologies in digital health that can impact the management of infectious diseases</li> <li>2. Evaluate opportunities for digital health and AI applications to improve antimicrobial use and outcomes</li> <li>3. List critical concepts for safe use and effective adoption of digital health platforms in infectious diseases and antimicrobial stewardship practice</li> </ol>
<b>11:45 am – 1:30 pm</b>	<b>Lunch on own</b>

11:45 am – 1:00 pm	<p><b>Satellite Symposium</b></p> <p><b>Title: Impact of COVID-19 on Certain Immunocompromised Patients</b>  Speaker: Cedric W. Spak, MD, MPH  Hosted by INVIVYD</p>
1:30 pm – 3:00 pm <b>AASP</b>	<p><b>Innovations in Diagnostic Laboratory Science and Stewardship</b>  ACPE Program #: 0485-0000-25-022-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: David R. Ha, PharmD</p> <p><b>Plenary 1A Advances in Diagnostic and Laboratory Science</b>  Speaker: Romney M. Humphries, PhD, D(ABMM)</p> <p><b>Plenary 1B Implications for Guidelines and Interprofessional Practice</b>  Speaker: Ashlan J. Kunz Coyne, PharmD, MPH</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Discuss optimal laboratory testing technologies and approaches to provide patient-centered care of infectious diseases</li> <li>2. Discuss challenges that impact the implementation of new diagnostic technologies in infectious diseases</li> <li>3. Examine common practices for pharmacists and other healthcare providers to optimize the use and outcomes of new diagnostic tests</li> </ol>
3:00 pm – 3:30 pm	<p><b>Break in Exhibit Hall</b></p>
3:00 pm – 3:30 pm	<p><b>Exhibit Theater in Exhibit Hall</b></p> <p><b>Title: The Changing Face of CRE: The Latest Trends in Prevalence, Sub-types, and Testing</b>  Speaker: Joseph L. Kuti, PharmD, FIDP, FCCP  Hosted by AbbVie Commercial</p>
3:30 pm – 5:00 pm <b>AASP</b>	<p><b>Stewardship in Challenging Populations</b>  ACPE Program #: 0485-0000-25-023-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: Meghan N. Jeffres, PharmD</p> <p><b>Plenary 2A Antimicrobials in Cancer and Immunocompromised Patients</b>  Speaker: Jerod L. Nagel, PharmD</p> <p><b>Plenary 2B Surgical and Critical Care Antimicrobial Stewardship</b>  Speaker: Robert G. Sawyer, MD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Identify antimicrobial stewardship priorities and challenges in immunocompromised and surgical/critically ill populations</li> <li>2. Describe antibiotic use metrics and outcomes relevant in immunocompromised and surgical/critically ill populations</li> <li>3. Explain the application of the Core Elements of Antimicrobial Stewardship in the context of immunocompromised and surgical/critically ill patient populations</li> <li>4. Create communication strategies to foster interdisciplinary stewardship cooperation</li> </ol>
5:00 pm – 6:30 pm	<p><b>Scientific Poster Session and Cocktail Reception in Exhibit Hall</b> <i>(not accredited)</i></p>

**Friday, May 30, 2025**

6:30 am – 6:00 pm	<b>Hospitality Desk</b>
-------------------	-------------------------

7:00 am – 8:00 am	<b>Continental Breakfast in Exhibit Hall</b>
8:00 am – 9:30 am <b>AASP</b>	<p><b>Contemporary PKPD</b>  ACPE Program #: 0485-0000-25-024-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: Michael J. Rybak, PharmD, MPH, PhD</p> <p><b>Plenary 3A What's New in PKPD and Breakpoints</b>  Speaker: Jason M. Pogue, PharmD</p> <p><b>Plenary 3B PKPD Clinical Applications and Outcomes</b>  Speaker: Marc H. Scheetz, PharmD, MSc</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Explain the application of PKPD principles in determining antimicrobial breakpoints</li> <li>2. Summarize recent literature on antimicrobial PKPD associated with patient outcomes</li> <li>3. Analyze applications of PKPD as an antimicrobial stewardship strategy</li> </ol>
9:30 am – 10:00 am	<b>Break in Exhibit Hall</b>
9:30 am – 10:00 am	<p><b>Exhibit Theater in Exhibit Hall</b></p> <p><b>Title: INFORM Surveillance Program Yearly Review</b>  Speaker: Erin K. McCreary, PharmD  Hosted by AbbVie Medical Affairs</p>
10:00 am – 11:30 am <b>AASP</b>	<p><b>New Developments in Antibacterial Drugs</b>  ACPE Program #: 0485-0000-25-025-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: Kerry L. LaPlante, PharmD</p> <p><b>Plenary 4A Preparing for the Pipeline</b>  Speaker: Ashlan J. Kunz Coyne, PharmD, MPH</p> <p><b>Plenary 4B Making the Most of New Agents on the Market</b>  Speaker: Pranita D. Tamma, MD, MHS</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Describe clinical and microbiological data and potential place in therapy for antimicrobials in the pipeline</li> <li>2. Explain potential place in therapy for antimicrobials new to the market</li> <li>3. Assess developments in antibiotics to target metallo-beta-lactamase producing infections</li> </ol>
11:30 am – 1:30 pm	<b>Lunch on own</b>
11:45 am – 1:30 pm	<p><b>Satellite Symposium</b></p> <p><b>Title: Reducing Risk of CRBSIs in Hemodialysis Patients: A Multi-Disciplinary Approach</b>  Speakers: Celina Medina and Anil Agarwal, MBBS, MD  Hosted by CorMedix</p>
1:30 pm – 3:00pm <b>AASP</b>	<p><b>Updates and Insights on Antimicrobial Resistance</b>  ACPE Program #: 0485-0000-25-026-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: David R. Ha, PharmD</p> <p><b>Plenary 5A Challenging Gram-positive Organisms</b>  Speaker: Cesar A. Arias, MD, MSc, PhD</p> <p><b>Plenary 5B Challenging Gram-negative Organisms</b>  Speaker: Jason M. Pogue, PharmD</p>

	<p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Identify challenging gram-negative and gram-positive pathogens</li> <li>2. Describe temporal trends in antimicrobial resistance</li> <li>3. Explain impact of emerging antimicrobial resistance on patient outcomes and treatment options</li> <li>4. Assess a mechanistic-based approach for treatment of difficult-to-treat infections</li> </ol>
<b>3:00 pm – 3:30 pm</b>	<b>Break in Exhibit Hall</b>
<b>3:30 pm – 5:00 pm</b> <b>AASP</b>	<p><b>Assessing the Gray in Gra(y)m-positive Bloodstream Infections</b>  ACPE Program #: 0485-0000-25-027-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: Susan L. Davis, PharmD</p> <p><b>Plenary 6A/6B Stepdown Therapies for Bloodstream Infections, Focus on Oral and Long-acting Injectable Options</b></p> <p>Speaker(s): Erin K. McCreary, PharmD  Zahra Kassamali Escobar, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Discuss approaches to the use of oral antibiotics for gram-positive bloodstream infections</li> <li>2. Describe evidence and controversies in the management of gram-positive bloodstream infection with dalbavancin and oritavancin</li> <li>3. Evaluate appropriate patient selection and monitoring in the use of oral antibiotics or long-acting injectables for bloodstream infections</li> </ol>
<b>5:00 pm – 6:00 pm</b>	<b>Exhibitor Reception in Exhibit Hall</b>

<b>Saturday, May 31, 2025</b>	
<b>6:30 am – 1:00 pm</b>	<b>Hospitality Desk</b>
<b>7:00 am – 8:00 am</b>	<b>Continental Breakfast in Foyer</b>
<b>8:00 am – 9:30 am</b>	<p><b>The Importance of Prevention and the Patient Experience</b>  ACPE Program #: 0485-0000-25-028-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: Susan L. Davis, PharmD</p> <p><b>Plenary 7A Prevention Essentials for Serious Infections</b>  Speaker: Marin L. Schweizer, PhD</p> <p><b>Plenary 7B Connecting the Head to Heart, Engaging Patients and Families in Quality and Safety, A Deep Transparent Partnership</b>  Speaker: Armando Nahum</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Discuss the importance of infection prevention practices in improving patient outcome and experience</li> <li>2. Summarize top priorities for infection prevention in vulnerable patient populations</li> <li>3. Develop strategies to engage patients in antimicrobial use policy and resistance education</li> </ol>
<b>9:30 am – 10:00 am</b>	<b>Break in Foyer</b>

<p><b>10:00 am – 11:30 am</b></p>	<p><b>Hot Topics! What You May Have Missed in ID This Year</b>  ACPE Program #: 0485-0000-25-029-L01-P (1.5 Contact Hours)  ACPE Activity Type: Application</p> <p>Moderator: Meghan N. Jeffres, PharmD</p> <p><b>Plenary 8A/8B Hot Topics: What Did You Miss in Infectious Diseases 2024-2025</b>  Speakers: Jamie L. Wagner, PharmD  Zahra Kassamali Escobar, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. Identify major developments published in the ID literature from May 2024 through April 2025</li> <li>2. Summarize important new clinical studies or guidelines impacting antimicrobial use and resistance</li> <li>3. Evaluate preliminary findings of key unpublished studies that were presented at recent ID conferences</li> </ol>
<p><b>11:30 am – 12:30 pm</b></p>	<p><b>Meet the Professors</b>  ACPE Program #: 0485-0000-25-030-L01-P (1.0 Contact Hour)  ACPE Activity Type: Application</p> <p>Facilitator: Michael J. Rybak, PharmD, MPH, PhD</p> <p>Panelists: Elizabeth S. Dodds Ashley, PharmD, MHS  Zahra Kassamali Escobar, PharmD  Jerod L. Nagel, PharmD  Pranita D. Tamma, MD, MHS  Jamie L. Wagner, PharmD</p> <p>Learning Objectives:  <i>Upon completion of this session, the participant will be able to:</i></p> <ol style="list-style-type: none"> <li>1. List the top antimicrobial controversies of 2024-2025</li> <li>2. Identify a therapeutic intervention to address multidrug resistant pathogens</li> <li>3. Evaluate an antimicrobial stewardship strategy or priority that directly relates to your practice or institution</li> </ol>
<p><b>12:30 pm</b></p>	<p><b>Meeting Adjourns</b></p>